跳至主要内容
临床试验/CTRI/2023/11/060203
CTRI/2023/11/060203尚未招募3 期

A three-arm, parallel group, open label, randomized trial of three supplements for the nutritional management of moderate wasting in children 6-24m of age with acute illness. - Nutri-MAM Study

Center for Public Health Kinetics0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age 6-24 months, and
  • 2.Moderately wasted i.e. WLZ =-2 and > -3 or MUAC < 125 mm and > 115 mm, and
  • 3.Presenting with any of the following acute illnesses at a facility out-patient clinic or discharged from hospital after <7d for any of the following:
  • a.diarrhea, defined as 3 or more loose or watery
  • stools (with or without blood) in the previous
  • 24 hours, and no dehydration on assessment. If
  • the child has dehydration, the dehydration will
  • be treated re-assessing for recruitment, or
  • b.pneumonia, defined as presence before of fast
  • breathing or chest indrawing, or
  • c.Non-malarial fever, defined as reported or
  • measured (= 38?C) fever of >3 days but < 7 days
  • d.malaria, defined as reported or measured (=
  • 38?C) fever and positive rapid diagnostic test, or
  • 4. Consent for study participation from parent or legal guardian

排除标准

  • 1.Severe acute malnutrition (WLZ < -3 or MUAC <115mm or oedema of both feet)
  • 2.General danger sign (lethargic/unconscious, convulsions, unable to drink, vomits everything)
  • 3.Severe illness (severe pneumonia or very severe disease, severe dehydration, neck stiffness)
  • 4.Persistent diarrhoea (=14d)
  • 5.Chronic infections/illness or disability, e.g. TB, HIV, congenital defects, cerebral palsy
  • 6.Require hospital admission
  • 7. Well child attended clinic only for routine growth monitoring or immunization
  • 8.Child receiving food supplements for moderate wasting
  • 9.Treated for moderate wasting in the previous 3 months
  • 10.Previously enrolled in the study
  • 11. Child lives outside the study area

研究者

发起方
Center for Public Health Kinetics

相似试验

进行中(未招募)
不适用
Pharmacodynamic effects of lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately controlled with insulin glargine with or without metformin.Type 2 Diabetes mellitusMedDRA version: 15.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2012-000027-40-DESanofi-Aventis Recherche & Développement
尚未招募
3 期
olanzipine antiemtic study
CTRI/2018/12/016643Tata Memorial Hospital
进行中(未招募)
1 期
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz. - SWEET StudyHuman immunodeficiency virus (HIV-1) infectionMedDRA version: 7.0Level: PTClassification code 10020161
EUCTR2004-002254-59-GBGilead Sciences Limited220
进行中(未招募)
1 期
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz. - SWEET StudyHuman immunodeficiency virus (HIV-1) infectionMedDRA version: 7.0 Level: PT Classification code 10020161
EUCTR2004-002254-59-IEGilead Sciences Limited220
进行中(未招募)
不适用
Effect of traditional ayurvedic formulation vs yoga vs conventional treatment in patients with Hypothyroidism.
CTRI/2021/12/038780Patanjali Research Institute governed by Patanjali Research Foundation Trust